The impact of fluoxetine on obesity and diabetes-related biomarkers in overweight and obese individuals: a systematic review and meta-analysis of randomized controlled trials

Abstract Background and aim Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), is widely used in clinical practice for managing depression and anxiety. Emerging evidence suggests fluoxetine may influence body weight (BW) and glucose metabolism, yet its potential benefits in overweight or o...

Descripció completa

Dades bibliogràfiques

Autors principals:	Guixia Tong, Chen Zhang, Hainan Li, Xin Gao, Periyannan Velu, Mohammad Safargar, Kousalya Prabahar, Hua Xie, Xiaoyan Wang
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2025-10-01
Col·lecció:	BMC Psychiatry
Matèries:	Fluoxetine Obesity Diabetes HbA1c Fasting blood sugar
Accés en línia:	https://doi.org/10.1186/s12888-025-07441-8
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!